The IGF2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 lung adenocarcinoma line, with targeted disruption of the IGF2 gene. This loss-of-function model eliminates endogenous IGF2 expression and provides a representative population for functional analyses, avoiding the bias of single-cell clones. The knockout cells enable study of the net phenotypic consequences of IGF2 deficiency in a cancer-relevant context.
The A-549 cell line, established from lung adenocarcinoma of a 58-year-old male, displays features of alveolar type II pneumocytes. It is a cornerstone model in lung cancer research and drug discovery, widely used for studying NSCLC biology including proliferation, apoptosis, and therapeutic response. Its genetic tractability and well-documented signaling characteristics make it an excellent host for CRISPR-mediated gene disruption.
IGF2 is a potent fetal growth factor that signals primarily through IGF1R and the insulin receptor. Upon ligand binding, the receptors recruit adaptor proteins IRS1 and IRS2, triggering activation of the PI3K-AKT1-mTOR and RAS-RAF-MEK-ERK cascades. AKT1 phosphorylates BAD and FOXO1 to promote survival, while mTORC1 stimulates riboprotein S6 kinase (RPS6KB1) to drive translation. ERK1/2 (MAPK3/MAPK1) upregulates cyclin D1 (CCND1) to facilitate G1/S transition. IGF2 expression is controlled by the H19/IGF2 imprinting control region and transcription factors E2F, SP1, and CTCF, and its activity is fine-tuned by binding to IGFBP3, IGFBP4, and IGFBP6. Dysregulation of this network contributes to oncogenic transformation.
In A-549 lung adenocarcinoma cells, autocrine IGF2 production drives constitutive activation of IGF1R and its downstream effectors, conferring growth and survival advantages typical of NSCLC. Disruption of the IGF2 gene in this model ablates ligand-driven receptor signaling, resulting in attenuation of both the PI3K-AKT and MAPK pathways. Consequently, the knockout phenotype exhibits reduced proliferation, impaired colony formation, and increased susceptibility to apoptosis, recapitulating the dependency of these cancer cells on IGF2 autocrine loops. This makes the IGF2 Knockout A-549 Polyclonal Cells a physiologically relevant tool for dissecting the role of IGF2 in tumor maintenance.
Researchers can employ this knockout model to interrogate IGF2-mediated oncogenic mechanisms, evaluate inhibitors targeting the IGF1R or downstream kinases, and study resistance pathways in lung adenocarcinoma. Typical assays include MTT proliferation assays, colony formation in soft agar, wound healing migration tests, Western blotting for phospho-AKT (Ser473) and phospho-ERK1/2, RT-qPCR quantification of IGF2 transcripts, and flow cytometric analysis of apoptosis. The cells are also suited for in vivo xenograft studies to assess tumor growth dependency on IGF2. For additional information or technical assistance, please contact Ascent Research.
